• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Opthea completes enrollment for sozinibercept (OPT-302) trials in pivotal Phase 3 program

News
Article

The COAST and ShORe trials have a total of 1984 patients enrolled for the treatment of wet age-related macular degeneration.

Older person holding eye Image Credit: AdobeStock/Satjawat

Image Credit: AdobeStock/Satjawat

Clinical stage biopharmaceutical company Opthea Limited has announced enrollment completion for the COAST and ShORe trials in the pivotal Phase 3 program for treatment of patients with wet age-related macular degeneration (AMD).1 The announcement follows the enrollment completion of the COAST trial from earlier this year.2

“Today marks the achievement of a key milestone for the sozinibercept global Phase 3 clinical trial program that brings us closer to our goal of improving visual outcomes for patients with wet AMD,” said Arshad M Khanani, MD, MA, FASRS, chief medical advisor of Opthea, in a news release. “In a large Phase 2b clinical trial of 366 treatment-naïve wet AMD patients, sozinibercept demonstrated strong clinical evidence of superior visual outcomes in combination with ranibizumab. These data formed the basis for this large, global Phase 3 clinical program.”

The trials are designed to assess the safety and superior efficacy of sozinibercept (OPT-302) along with standard-of-care anti-VEGF-A therapies in the treatment of patients with wet AMD.1 Superiority in visual outcomes were demonstrated in Phase 2b of the program, according to the release.

Between the 2 multicenter, double-masked, randomized, sham controlled trials, 1984 patients were enrolled, with 998 patients in COAST and 986 in ShORe. Over the course of 2 years, COAST will assess the safety and tolerability of 2.0 mg sozinibercept administered intravitreally in addition to 2.0 mg aflibercept, with ShORe patients being administered 0.5 mg of ranibizumab instead of aflibercept. The primary endpoint for both trials is the mean change in Best Corrected Visual Acuity from baseline to week 52.1

“Sozinibercept is the only late-stage asset in development in over 15 years that is targeting better visual outcomes for wet AMD patients in combination with standard-of-care anti-VEGF-A therapies,” said Frederic Guerard, PharmD, chief executive officer of Opthea, in the release. “We are excited about the potential of sozinibercept to transform the current treatment paradigm, with pivotal 52-week topline data expected in mid-CY2025 to support a potential BLA submission.”

References:
  1. Opthea completes enrollment in pivotal Phase 3 clinical program with sozinibercept in wet AMD. News release. Opthea Limited. May 28, 2024. Accessed May 29, 2024. https://ir.opthea.com/news-releases/news-release-details/opthea-completes-enrollment-pivotal-phase-3-clinical-program
  2. Joy J. Opthea Limited completes enrollment for 1 of 2 Phase 3 sozinibercept (OPT-302) trials. Optometry Times. February 19, 2024. Accessed May 29, 2024. https://www.optometrytimes.com/view/opthea-limited-completes-enrollment-for-1-of-2-phase-3-sozinibercept-opt-302-trials
Related Videos
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
© 2024 MJH Life Sciences

All rights reserved.